menu
    • menu

    Company profile for Biodexa Pharmaceuticals

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company’s lead ca...
    Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, medulloblastoma and paediatric diffuse midline glioma.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Biodexa Pharmaceuticalsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    1 Caspian Point Caspian Way Cardiff CF10 4DQ
    Telephone
    Telephone
    +44 (0)2920480180
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://biodexapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biodexa/?originalSubdomain=uk
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/biodexa_pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biodexa Announces Pricing Of $10 Million Public Offering
    Biodexa Announces Pricing Of $10 Million Public Offering

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207701/0/en/Biodexa-Announces-Pricing-of-10-Million-Public-Offering.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Biodexa Enrolls First EU Patients in Pivotal Serenta FAP Trial
    Biodexa Enrolls First EU Patients in Pivotal Serenta FAP Trial

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3197009/0/en/Biodexa-Announces-Enrolment-of-First-European-Patients-into-Pivotal-Phase-3-Serenta-Trial-in-FAP.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    Biodexa Initiates First European Site For Phase 3 Serenta Trial
    Biodexa Initiates First European Site For Phase 3 Serenta Trial

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/24/3193509/0/en/Biodexa-Activates-First-European-Site-for-Registrational-Phase-3-Serenta-Trial-in-FAP.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share
    Biodexa Gets Europe CTA Approval For Phase 3 Serenta Trial
    Biodexa Gets Europe CTA Approval For Phase 3 Serenta Trial

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179260/0/en/Biodexa-Announces-Approval-of-CTA-in-Europe-for-Phase-3-Serenta-Trial-in-FAP-First-European-patient-expected-to-be-enrolled-in-4Q-2025-Addressable-US-European-Market-Put-at-7-Billi.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Biodexa Hosts FAP Mechanisms Symposium At CGA – IGC Conference
    Biodexa Hosts FAP Mechanisms Symposium At CGA – IGC Conference

    06 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/06/3161708/0/en/Biodexa-to-Host-Breakfast-Symposium-on-FAP-Mechanisms-and-Chemoprevention-Trial-Issues-at-CGA-IGC-Conference-on-October-11-2025.html

    GLOBENEWSWIRE
    06 Oct 2025
    Share Share
    Interim Results for Six Months Ending June 30, 2025
    Interim Results for Six Months Ending June 30, 2025

    12 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/12/3149201/0/en/Interim-results-for-the-six-months-ended-June-30-2025.html

    GLOBENEWSWIRE
    12 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search